Category list : Antineoplastic agents
Sort by: Newest first Oldest first A-Z Z-A
-
Temozolomide for melanoma
Temozolomide (Temodal) is as effective as dacarbazine for metastatic melanoma and has the advantage of being an oral preparation, say Dr Mark Middleton (department of medical oncology, Christie hospital NHS trust, Manchester) and colleagues.
-
New cancer drugs might also find use in heart disease Subscription
The reports on this and the next page are from the XIIth International Symposium on Atherosclerosis which was held in Stockholm on June 25-29
-
MTX melanoma risk
Patients with rheumatoid arthritis (RA) who are treated with methotrexate are at increased risk of melanoma and other malignancies, a new review of data suggests. Researchers in Australia identified 87 malignancies among 459 RA patients who had been treated with methotrexate.
-
Pegylated interferon provides benefits in stage III melanoma
Prolonged treatment with adjuvant pegylated interferon alfa-2b improves recurrence-free survival in patients with stage III melanoma, results of a phase III study suggest (Lancet 2008;372:117).
-
New study finds no link between antioxidants and melanoma risk
Vitamin and mineral supplements containing antioxidants are not associated with an increased melanoma risk, according to new research published in the Archives of Dermatology (2009;8:879).
-
Target high-risk people for melanoma screening
Targeting high-risk individuals for screening could be the best way to improve early detection and treatment of malignant melanoma Alexander Stratigos, of the department of dermatology at the University of Athens Medical School, told the audience during a session at the European Association of Dermatology and Venereology 2010 Spring Symposium.
-
Low-dose methotrexate and NSAIDs Subscription
This theoretical case highlights issues regarding the use of non-steroidal anti-inflammatory drugs by patients on methotrexate, advice that pharmacists can give, and the warning signs of adverse effects
-
Pioglitazone cardiac risk and risk of jaw osteonecrosis with some antineoplastic drugs highlighted
Pioglitazone should be discontinued if any deterioration in a patient’s cardiac status occurs, according to the latest Drug Safety Update (January 2011).
-
Ipilimumab improves melanoma survival in trials
A phase III study suggests the human monoclonal antibody ipilimumab, in combination with dacarbazine, improves overall survival in patients with previously untreated metastatic melanoma.
-
Vemurafenib shows potential as targeted melanoma therapy
Genetically-targeted chemotherapy combinations based on the BRAF-kinase inhibitor vemurafenib are going on trial for the treatment of metastatic malignant melanoma.
Show 10 per page20 per page50 per page
